IL283450B2 - Solid solution capsule formulations comprising (2r,3s)-2-(4-(cyclopentylamino)phenyl)-1-(2-fluoro-6-methylbenzoyl)-n-(4-methyl-3- (trifluoromethyl)phenyl)piperidine-3-carboxamide, methods for their preparation and therapeutic uses thereof - Google Patents

Solid solution capsule formulations comprising (2r,3s)-2-(4-(cyclopentylamino)phenyl)-1-(2-fluoro-6-methylbenzoyl)-n-(4-methyl-3- (trifluoromethyl)phenyl)piperidine-3-carboxamide, methods for their preparation and therapeutic uses thereof

Info

Publication number
IL283450B2
IL283450B2 IL283450A IL28345021A IL283450B2 IL 283450 B2 IL283450 B2 IL 283450B2 IL 283450 A IL283450 A IL 283450A IL 28345021 A IL28345021 A IL 28345021A IL 283450 B2 IL283450 B2 IL 283450B2
Authority
IL
Israel
Prior art keywords
solid solution
peg
capsule formulation
solution capsule
ionic surfactant
Prior art date
Application number
IL283450A
Other languages
English (en)
Hebrew (he)
Other versions
IL283450A (en
IL283450B1 (en
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=70849818&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL283450(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Publication of IL283450A publication Critical patent/IL283450A/en
Publication of IL283450B1 publication Critical patent/IL283450B1/en
Publication of IL283450B2 publication Critical patent/IL283450B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL283450A 2018-11-30 2019-11-27 Solid solution capsule formulations comprising (2r,3s)-2-(4-(cyclopentylamino)phenyl)-1-(2-fluoro-6-methylbenzoyl)-n-(4-methyl-3- (trifluoromethyl)phenyl)piperidine-3-carboxamide, methods for their preparation and therapeutic uses thereof IL283450B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862773848P 2018-11-30 2018-11-30
PCT/US2019/063547 WO2020112961A1 (en) 2018-11-30 2019-11-27 Capsule formulations

Publications (3)

Publication Number Publication Date
IL283450A IL283450A (en) 2021-07-29
IL283450B1 IL283450B1 (en) 2024-02-01
IL283450B2 true IL283450B2 (en) 2024-06-01

Family

ID=70849818

Family Applications (1)

Application Number Title Priority Date Filing Date
IL283450A IL283450B2 (en) 2018-11-30 2019-11-27 Solid solution capsule formulations comprising (2r,3s)-2-(4-(cyclopentylamino)phenyl)-1-(2-fluoro-6-methylbenzoyl)-n-(4-methyl-3- (trifluoromethyl)phenyl)piperidine-3-carboxamide, methods for their preparation and therapeutic uses thereof

Country Status (31)

Country Link
US (4) US20200170957A1 (https=)
EP (3) EP4487915A3 (https=)
JP (1) JP7342124B2 (https=)
KR (1) KR102586747B1 (https=)
CN (1) CN113164403A (https=)
AR (1) AR117219A1 (https=)
AU (1) AU2019389031B2 (https=)
BR (1) BR112021010285A2 (https=)
CA (1) CA3120999C (https=)
CL (1) CL2021001389A1 (https=)
CY (1) CY1126079T1 (https=)
DK (2) DK3886820T3 (https=)
ES (2) ES2998858T3 (https=)
FI (2) FI3886820T3 (https=)
HR (2) HRP20230551T1 (https=)
HU (2) HUE069633T2 (https=)
IL (1) IL283450B2 (https=)
LT (2) LT4233850T (https=)
MA (2) MA54318B1 (https=)
MD (2) MD3886820T2 (https=)
MX (1) MX2021006242A (https=)
NZ (1) NZ776554A (https=)
PL (2) PL4233850T3 (https=)
PT (2) PT4233850T (https=)
RS (2) RS64250B1 (https=)
SG (1) SG11202105572UA (https=)
SI (2) SI4233850T1 (https=)
SM (2) SMT202400521T1 (https=)
TW (1) TWI827745B (https=)
WO (1) WO2020112961A1 (https=)
ZA (1) ZA202103820B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020112961A1 (en) 2018-11-30 2020-06-04 Chemocentryx, Inc. Capsule formulations
US11603356B2 (en) 2019-11-08 2023-03-14 Chemocentryx, Inc. Amorphous form of a complement component C5a receptor
CN116529241A (zh) * 2020-10-28 2023-08-01 坎莫森特里克斯公司 治疗化脓性汗腺炎的方法
JP7839157B2 (ja) * 2020-10-28 2026-04-01 ケモセントリックス， インコーポレイテッド 化膿性汗腺炎を処置する方法
WO2022140258A1 (en) * 2020-12-21 2022-06-30 Chemocentryx, Inc. Treatment of c3 glomerulopathy using a c5a inhibitor
CN119031903A (zh) * 2022-05-19 2024-11-26 陶氏环球技术有限责任公司 基于peg的聚合物间复合物用于改善bcs ii类药物的增溶的用途
WO2025203055A1 (en) * 2024-03-26 2025-10-02 Council Of Scientific And Industrial Research Encapsulated dihydrofolate formulation for dietary supplementation as effective nutraceutical supplement and method of preparation thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110086844A1 (en) * 2002-02-14 2011-04-14 Solvay Pharmaceuticals B.V. Oral Solid Solution Formulation of a Poorly Water-Soluble Active Substance
US20180179160A1 (en) * 2010-06-24 2018-06-28 Chemocentryx, Inc. C5ar antagonists

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0518484A2 (pt) 2004-11-24 2008-11-18 Merck & Co Inc composiÇço, cÁpsula, e, processo para preparar a mesma
DE102005053066A1 (de) 2005-11-04 2007-05-10 Basf Ag Verwendung von Copolymeren als Solubilisatoren für in Wasser schwerlöslichen Verbindungen
CA2689137C (en) * 2007-05-29 2017-05-02 Intrexon Corporation Chiral diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
RS54998B1 (sr) 2008-12-22 2016-11-30 Chemocentryx Inc Antagonisti c5ar
NZ602288A (en) * 2010-03-10 2014-02-28 Abbvie Bahamas Ltd Solid compositions comprising amorphous (2r,6s,13as,14ar,16as,z)-n-(cyclopropylsulfonyl)-6-(5-methylpyrazine-2-carboxamido)-5,16-dioxo-2-(phenanthridin-6-yloxy)-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a-carboxamide
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US9074470B2 (en) 2010-12-27 2015-07-07 Seven Generations Energy Ltd. Methods for drilling and stimulating subterranean formations for recovering hydrocarbon and natural gas resources
WO2015118015A1 (en) 2014-02-05 2015-08-13 Lek Pharmaceuticals D.D. Solid pharmaceutical compositions of androgen receptor antagonists
DK3200791T3 (da) 2014-09-29 2020-05-25 Chemocentryx Inc Fremgangsmåder og mellemprodukter i fremstilling af C5AR- antagonister
JP7339733B2 (ja) 2016-01-14 2023-09-06 ケモセントリックス，インコーポレイティド Ｃ３腎症を処置する方法
EP3439658B1 (en) 2016-04-04 2021-11-24 ChemoCentryx, Inc. Soluble c5ar antagonists
TWI826364B (zh) 2017-04-03 2023-12-21 德商因夫萊亞斯有限公司 活性抑制劑於發炎性疾病之治療
CA3077395A1 (en) 2017-10-30 2019-05-09 Chemocentryx, Inc. Deuterated compounds as immunomodulators
CA3078732A1 (en) 2017-10-31 2019-05-09 Chemocentryx, Inc. C5ar inhibitor reduction of urinary scd163
US11191756B2 (en) 2018-06-07 2021-12-07 Chemocentryx, Inc. Dosing and effect of C5a antagonist with ANCA-associated vasculitis
WO2020112961A1 (en) 2018-11-30 2020-06-04 Chemocentryx, Inc. Capsule formulations

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110086844A1 (en) * 2002-02-14 2011-04-14 Solvay Pharmaceuticals B.V. Oral Solid Solution Formulation of a Poorly Water-Soluble Active Substance
US20180179160A1 (en) * 2010-06-24 2018-06-28 Chemocentryx, Inc. C5ar antagonists

Also Published As

Publication number Publication date
EP4487915A3 (en) 2025-03-19
SG11202105572UA (en) 2021-06-29
US20220233453A1 (en) 2022-07-28
IL283450A (en) 2021-07-29
HRP20241735T1 (hr) 2025-02-28
WO2020112961A1 (en) 2020-06-04
US20200170957A1 (en) 2020-06-04
BR112021010285A2 (pt) 2021-08-17
JP2022510304A (ja) 2022-01-26
CN113164403A (zh) 2021-07-23
JP7342124B2 (ja) 2023-09-11
US20240299306A1 (en) 2024-09-12
AU2019389031B2 (en) 2023-06-15
DK3886820T3 (da) 2023-05-15
CA3120999C (en) 2025-04-01
EP3886820B1 (en) 2023-04-12
LT3886820T (lt) 2023-06-12
PT3886820T (pt) 2023-05-24
MA62992B1 (fr) 2025-01-31
KR20210098489A (ko) 2021-08-10
MX2021006242A (es) 2021-09-10
EP3886820A4 (en) 2022-08-24
CY1126079T1 (el) 2023-11-15
MD4233850T2 (ro) 2025-02-28
PL4233850T3 (pl) 2025-03-17
KR102586747B1 (ko) 2023-10-06
MA54318B1 (fr) 2023-08-31
LT4233850T (lt) 2025-01-27
PL3886820T3 (pl) 2023-08-14
EP3886820B8 (en) 2023-05-17
HUE069633T2 (hu) 2025-04-28
EP4233850A3 (en) 2023-09-20
HUE062551T2 (hu) 2023-11-28
FI4233850T3 (fi) 2024-12-30
EP3886820A1 (en) 2021-10-06
ES2943492T3 (es) 2023-06-13
FI3886820T3 (fi) 2023-05-25
MA54318A (fr) 2021-10-06
RS66362B1 (sr) 2025-01-31
MD3886820T2 (ro) 2023-07-31
ES2998858T3 (en) 2025-02-21
US20250375385A1 (en) 2025-12-11
TW202038952A (zh) 2020-11-01
CA3120999A1 (en) 2020-06-04
AR117219A1 (es) 2021-07-21
HRP20230551T1 (hr) 2023-08-18
EP4487915A2 (en) 2025-01-08
SMT202400521T1 (it) 2025-01-14
US11951214B2 (en) 2024-04-09
ZA202103820B (en) 2026-03-25
AU2019389031A1 (en) 2021-06-17
IL283450B1 (en) 2024-02-01
NZ776554A (en) 2024-12-20
DK4233850T3 (da) 2025-01-02
EP4233850B1 (en) 2024-10-02
SI3886820T1 (sl) 2023-07-31
SMT202300153T1 (it) 2023-09-06
SI4233850T1 (sl) 2025-03-31
TWI827745B (zh) 2024-01-01
RS64250B1 (sr) 2023-06-30
EP4233850A2 (en) 2023-08-30
CL2021001389A1 (es) 2021-12-24
PT4233850T (pt) 2024-12-30

Similar Documents

Publication Publication Date Title
IL283450B2 (en) Solid solution capsule formulations comprising (2r,3s)-2-(4-(cyclopentylamino)phenyl)-1-(2-fluoro-6-methylbenzoyl)-n-(4-methyl-3- (trifluoromethyl)phenyl)piperidine-3-carboxamide, methods for their preparation and therapeutic uses thereof
CN101945648B (zh) 含甘磷酸胆碱的药物制品
US11466067B2 (en) Compositions, formulations and interleukin production and purification
BR122013001996B1 (pt) Nanocorpos melhorados contra fator alfa de necrose tumoral
JP5926243B2 (ja) 経口薬物療法のための方法および組成物
JP2022510304A5 (https=)
CN114641289A (zh) 补体成分C5a受体的游离碱晶型
JP2026016449A (ja) 補体成分Ｃ５ａ受容体の非晶質形態
KR20220133176A (ko) 바다두스타트를 사용하는 치료 방법
JP2017031209A (ja) アタシセプトなどのＴＡＣＩ−Ｉｇ融合タンパク質を用いた自己免疫疾患を治療するための投薬法
WO2020077010A1 (en) Lactococcus lactis expression system for delivering proteins efficacious for the treatment of epithelial barrier function disorders
TWI714560B (zh) 包含安洛待平（ａｍｌｏｄｉｐｉｎｅ）、洛沙坦（ｌｏｓａｒｔａｎ）及氯薩利酮（ｃｈｌｏｒｔｈａｌｉｄｏｎｅ）的醫藥複合調配物
CN115916257A (zh) PGD2/DPr2和血栓素A2/TPr受体的双重拮抗剂及其用于治疗适应不良免疫反应或血栓性素质的用途
TWI233803B (en) Anti-inflammatory factor, method of isolation, and use
JP2022506891A (ja) Ｎｌｒｐ活性に関連する状態を処置するための化合物及び組成物
Kizior et al. Saunders Nursing Drug Handbook 2019 E-Book: Saunders Nursing Drug Handbook 2019 E-Book
TW200536546A (en) A method for the prevention of thrombotic, embolic and/or hemorrhagic disorders
KR101730399B1 (ko) 악시티닙을 포함하는 약물 전달체 및 이의 제조방법
JP5872769B2 (ja) 冬虫夏草菌糸体抽出物を有効成分として含む移植片拒絶抑制用組成物
US20200239532A1 (en) Recombinant fusion protein of baf57 and uses thereof
AU2016265974A1 (en) Tuberculosis drug based on 4-thioureido-iminomethylpyridinium perchlorate: method of preparation and treatment
Ilbäck et al. Effects of a superantigen-antibody recombinant fusion protein (r-C242 Fab-SEA) on toxicological responses in the anaesthetised rabbit
US20220192992A1 (en) Protection of monoclonal antibody integrity against evaporative solidification, compression and proteolysis by dextran and cyclodextrin derivatives
WO2025140517A1 (zh) 一种药物组合物及其应用
RU2021118878A (ru) Лекарственные формы в виде капсул